Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 10Breast Neoplasms 5Sarcoma 3Prostatic Neoplasms 3Fallopian Tube Neoplasms 3Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Recurrence 1Platinum-sensitive Relapsed Ovarian Cancer 1Osteosarcoma 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Metastatic Castration Resistant Prostate Cancer 1Kenny-Caffey syndrome, Type 1 1Her-2 Negative Breast Cancer 1Glioblastoma 1Female Breast Cancer Patients 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Cancer Metastatic 1Advanced Solid Tumors 1Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

Fulvestrant 5Letrozole 3Capecitabine 3ribociclib 2exemestane 2dalpiciclib 2apatinib 2Irinotecan 2Gemcitabine 2Anastrozole 2tusamitamab ravtansine 1trastuzumab deruxtecan 1sacituzumab govitecan 1pegfilgrastim 1palbociclib 1margetuximab 1irinotecan sucrosofate 1fluzoparib 1abemaciclib 1Vinorelbine 1Trastuzumab 1Tamoxifen 1Paclitaxel 1Liposomes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Cancer Metastatic × fluzoparib × Clear all
NCT05759546 2024-02-06

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Fudan University

Phase 2 Recruiting
200 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡